Russian pharmaceutical industry shines at the BIO International Convention 2013

Print 30 April 2013
Modern Russia

The Russian pharmaceutical industry made its mark at this year’s BIO International Convention in Chicago. Sergey Tsyb, Director of the Department of Chemical Industries and Bioengineering Technologies at the Russian Ministry of Industry and Trade, highlighted the government’s strategy for Russian pharmaceutical development at the “Spotlight on the BRICS: Russia” session on Monday.

The State Duma, Russian pharmaceutical companies and regional pharmaceutical clusters also participated in the session, which focused on the recent regulatory changes in Russia and the initial results of “Pharma 2020,” the government’s initiative to develop the pharmaceutical and medical industry.

“This is our third year at the BIO convention and so far our experience has been very positive,” said Tsyb, who also opened the Russian Pavilion booth at the convention. “We have seen a remarkable shift in opinions about pharmaceuticals in Russia in the past few years. Pharma 2020 has already become a ubiquitous term across the world.”

As part of developing the industry – already valued at $21.4 billion in 2012 – the Pharma 2020 initiative aims to increase innovation in medicines and medical technology with a focus on syncing the Russian pharmaceutical industry with international standards.

“We want to make sure Russian citizens have access to quality medications that are affordable and adhere to current international standards,” said Tsyb. “To ensure that medication stays affordable, as part of Pharma 2020 project, we are creating policy that supports local manufactures and keeps unfair competition in check.”
Tsyb believes that all domestic Russian companies will be manufacturing according to international standards by January 1, 2014. To help achieve this goal, Tsyb emphasized the importance of both theoretical and applied learning: “We are creating a new type of educational institution that gives theoretical knowledge combined with practical experience in biotechnology.”

The success of the Russian delegation at this year’s BIO International Convention will likely spur increased progress toward Pharma 2020 goals, informing and facilitating international partnership opportunities and most importantly, giving the Russian people quality medicine.

Source

 

Return